AptarGroup, Inc. Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. AptarGroup, Inc. is a global manufacturer of dispensing, dosing, and protection technologies for the pharmaceutical, beauty, and food/beverage markets. The company operates through three segments: Aptar Pharma, Aptar Beauty, and Aptar Closures.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $887.3 million | $915.4 million |
| Operating Income | $113.4 million | $112.1 million |
| Net Income (Attributable to Aptar) | $78.8 million | $83.1 million |
| Diluted EPS | $1.17 | $1.23 |
| Adjusted EBITDA | $183.3 million | $178.8 million |
| Free Cash Flow | $25.9 million | $16.7 million |
| Cash and Equivalents | $125.8 million | $199.8 million |
| Total Debt | $1.01 billion | $1.03 billion |
| Effective Tax Rate | 25.8% | 20.5% |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3% year-over-year, primarily due to a 3% negative impact from foreign currency exchange rates. On a core sales basis (excluding currency and acquisitions), sales were flat.
- Segment Performance:
- Aptar Pharma: Sales increased 1% (3% core growth) driven by strong prescription drug and active material science volumes. Adjusted EBITDA margin improved to 34.8%.
- Aptar Beauty: Sales decreased 7% (3% core decline) due to softer European demand for prestige fragrance and facial skincare. Adjusted EBITDA margin declined to 12.1%.
- Aptar Closures: Sales decreased 5% (2% core decline) due to lower tooling sales, offset by growth in food/beverage markets. Adjusted EBITDA margin improved to 15.8%.
- Profitability: Operating income increased slightly to $113.4 million despite lower sales, aided by cost management initiatives and improved product mix. However, Net Income declined due to a higher effective tax rate (25.8% vs. 20.5%) driven by a temporary French surtax and lower tax benefits from share-based compensation.
- Capital Allocation: The company repurchased approximately 548,000 shares for $80.0 million. Capital expenditures decreased to $56.9 million from $75.7 million in the prior year.
Guidance, Outlook, and Risks
- Q2 2025 Guidance: Management expects diluted earnings per share in the range of $1.56 to $1.64, excluding restructuring, investment fair value changes, and acquisition costs. This guidance assumes an effective tax rate of 19% to 21% due to a one-time tax benefit.
- Capital Expenditures: Total 2025 estimated cash outlays for capital expenditures are expected to be approximately $280 million to $300 million.
- Key Risks:
- Foreign Currency: Significant exposure to the Euro, Chinese Yuan, and other currencies; a strengthening USD has a dilutive effect.
- Geopolitical & Trade: Risks related to global conflicts (e.g., Ukraine), tariffs, and supply chain disruptions.
- Raw Materials: Availability and cost of materials, particularly sole-sourced components for Pharma solutions.
- Legal Contingencies: Ongoing defense against customs duty assessments totaling approximately $10–11 million in principal plus interest/penalties.
Investor Verification Checklist
- Core Sales Stability: Verify if the flat core sales growth in Q1 is sustainable given the divergence between Pharma growth and Beauty/Closures declines.
- Tax Rate Volatility: Monitor the impact of the French surtax and the realization of the one-time tax benefit mentioned in Q2 guidance.
- Debt Maturities: Review the $125 million senior unsecured notes due in 2025 and the company's refinancing strategy.
- Restructuring Progress: Track the execution of the "Optimization initiative" ($2.0 million expense in Q1) to ensure cost savings materialize.
- Investment Valuation: Assess the impact of the $1.1 million unrealized loss on the PureCycle investment and other equity securities.